Dr. Alaaeldin Ahmed Hamza, earned his PhD from Cairo University in Animal Physiology, is currently working as professor of Physiology in the National Organization for Drug Control and Research (NODCAR) Egypt. He is established scientist in the areas of liver toxicity, reproductive toxicity and liver cancer. For his highly cited publications he has ranked as the top scientists in United Arab Emirates institutions according to GSC public profiles 2017 and among the top 2% of researchers in the world by Stanford University in 2020. He has published more than 40 papers in different fields of pharmacology in many prestigious journal such as Hepatology, Scientific Report, Toxicology Letters, Toxicology, Food and Chemical Toxicology, Andrologia, Life Sciences and Molecules. His current Scopus H-index is 24 and his total citations are 2520. He is serving as a reviewer in Elsevier, Taylor, Springer and Wiley journals. He has been serving as an editorial board member of more than five international medical journals. He has participated in various national and international conferences. He has awarded the Best Individual Non Funded Research Project Award, the 9th Annual Research Conference, U.A.E. University, Al-Ain. April 21-23, 2008. ). He is member in National Committee for Biological Science. Egyptian Academy of Scientific Research and Technology. 22-10-2018-until now. He recognized as one of the best reviewers in Elsevier (2011& 2017). He is member in National Committee for Biological Science. Egyptian Academy of Scientific Research and Technology. 22-10-2018-until now. He recognized as one of the best reviewers in Elsevier (2011& 2017). His research focus areas are the development of animal models to study the protective effects of natural substances and antioxidant and oxidative stress induced by pharmacological agents such as anticancer drugs and pharmacological agents. For last 7 years, He was involved in developing in in vivo and enzyme assays in the field of cancer and oxidative stress researches. His experience has involved drug discovery, mechanism-of-action studies, biomarker development, cancer pharmacology in xenograft and chemical tumor models, pharmacology of stress response signaling. This has required a broad understanding of cancer biology and pharmacology.